Danicopan not checked

Alexion Pharmaceuticals, Inc. · ALXN2040 · ACH-4471

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
2 active
26 in total · 4 in the EU

What this is

How it works
Complement Factor D Inhibitor FDA class
How it’s given
“Participants will receive danicopan on a weight-based dosing regimen.”In the company’s words, NCT06449001 on ClinicalTrials.gov
Tested for
Paroxysmal Nocturnal Hemoglobinuria (2 trials), PNH, Extravascular Hemolysis
Main trialPhase 3
“This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.”In the company’s words, NCT05389449 on ClinicalTrials.gov
Other names
ALXN2040 · ACH-4471 · 4471 · ACH-0144471

Other drugs for Paroxysmal Nocturnal Hemoglobinuria

All 23 drugs for Paroxysmal Nocturnal Hemoglobinuria

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials26

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 24 Aug 2026 A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Phase 3Recruiting 28 May 2027 Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Phase 3Completed 29 Jun 2022 Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
Phase 2Completed 14 Nov 2018 Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2Completed 21 Dec 2018 A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
Phase 2Completed 20 Sep 2019 Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
Phase 2Completed 11 Dec 2019 A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
Phase 2Terminated 29 Mar 2021 A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Phase 2Completed 4 Jan 2022 A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2Terminated 5 Jul 2024 A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Phase 1Completed 21 Jun 2016 Study of a Single Dose of Danicopan in Healthy Participants
Phase 1Completed 5 Oct 2016 Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants
Phase 1Completed 11 Jan 2017 Study of Multiple Doses of Danicopan in Healthy Participants
Phase 1Completed 2 Jun 2017 A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
Phase 1Completed 15 Oct 2017 Study of Radiolabeled Danicopan in Healthy Male Participants
Phase 1Completed 21 Mar 2018 A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
Phase 1Completed 29 May 2018 Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
Phase 1Completed 21 Sep 2018 Study of Danicopan in Participants With Hepatic Impairment
Phase 1Completed 12 Oct 2018 A Study of the Cardiac Effects of Danicopan in Healthy Adults
Phase 1Completed 17 Oct 2018 A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
Phase 1Completed 14 Oct 2019 A Drug Interaction Study of Danicopan
Phase 1Completed 28 Sep 2020 Study of Danicopan in Participants of Japanese Descent
Phase 1Completed 7 Dec 2020 Study of the Metabolism of Danicopan in Healthy Adults
Phase 1Completed 3 Feb 2021 A Study of the Effects of Food and Age on Danicopan
Phase 1Completed 23 Mar 2023 Potential Drug Interaction Between ALXN2040 and Rosuvastatin
Phase 2Ended not given Proof of concept study to assess the efficacy and safety of Danicopan (factor D inhibitor) in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment (DANICSU).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Danicopan

Following is part of Solo: you see every change to Danicopan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in